Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

By sjmartinez • June 27, 2024

French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417. Epub ahead of print. PMID: 38922338.

Tags: Endocrinology, Harbor UCLA, Publications

Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease

Ko M, Barai R, Brent G. Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease. Cureus. 2024 Oct 15;16(10):e71551. doi: 10.7759/cureus.71551.[...]

Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer

Schumm MA, Nikiforov YE, Nikiforova MN, Wald AI, Tseng CH, Smooke-Praw S, Wu JX, Yeh MW, Livhits MJ. Association of BRAF V600E allele frequency with[...]

The Relationship Between Hospital Safety-Net Burden on Outcomes for High-Volume Thyroid Cancer Surgeons

Huston-Paterson HH, Mao YV, Tseng CH, Kim J, Chen DW, Wu JX, Yeh MW. The Relationship Between Hospital Safety-Net Burden on Outcomes for High-Volume Thyroid[...]